CLB Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
132.1M
+6.0%
124.6M
+2.3%
121.8M
-11.9%
138.3M
+2.8%
134.5M
Cost of Revenue
105.1M
+3.7%
101.4M
-0.7%
102.1M
-6.8%
109.5M
+4.4%
104.9M
Gross Profit
27.0M
+16.1%
23.2M
+17.8%
19.7M
-31.4%
28.7M
-3.0%
29.6M
Operating Expenses
14.9M
+5.9%
14.1M
-21.0%
17.8M
+38.2%
12.9M
+48.5%
8.7M
R&D
0
0
0
0
0
SG&A
11.3M
+2.9%
11.0M
-25.6%
14.7M
+38.4%
10.6M
-0.5%
10.7M
Operating Income
12.1M
+31.8%
9.2M
+384.9%
1.9M
-88.1%
15.8M
-24.4%
20.9M
EBITDA
15.8M
+21.7%
13.0M
+129.6%
5.7M
-71.0%
19.5M
-20.5%
24.5M
Net Income
5.5M
-5.8%
5.8M
+870.0%
-753000
-114.7%
5.1M
-64.7%
14.5M
EPS (Basic)
$0.12
-7.7%
$0.13
+750.0%
$-0.02
-120.0%
$0.10
-67.7%
$0.31
EPS (Diluted)
$0.12
-7.7%
$0.13
+750.0%
$-0.02
-122.2%
$0.09
-70.0%
$0.30
Shares (Diluted)
46.7M
-0.4%
46.9M
+1.7%
46.1M
-1.8%
46.9M
-0.4%
47.1M
Core Laboratories (CLB) — Financials